Biote (BTMD) Current Deferred Revenue (2021 - 2026)

Biote's Current Deferred Revenue history runs 6 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Current Deferred Revenue fell 6.19% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (down 6.19% YoY), while the FY2025 annual figure was $3.0 million, up 1.89% from the prior year.
• Current Deferred Revenue was $2.8 million for Q1 2026 at Biote, down from $3.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $3.2 million in Q3 2025 to a low of $1.9 million in Q2 2022.
• Historically, Current Deferred Revenue has averaged $2.7 million across 5 years, with a median of $2.9 million in 2024.
• The sharpest annual moves came in 2023 and 2026: Current Deferred Revenue jumped 52.77% in 2023, then decreased 6.19% in 2026.
• A 5-year view of Current Deferred Revenue shows it stood at $2.0 million in 2022, then surged by 52.77% to $3.0 million in 2023, then declined by 1.37% to $3.0 million in 2024, then grew by 1.89% to $3.0 million in 2025, then declined by 5.6% to $2.8 million in 2026.
• The last three Current Deferred Revenue figures came in at $2.8 million (Q1 2026), $3.0 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.